US Patent 7,732,430 Landscape: What Is Claimed for Oral Estrogen-Progestin Contraception, What Is Covered by Method-of-Use and Kit Claims, and How the Estate Blocks Generic and OTC-Style Design-Arounds
US Patent 7,732,430 is directed to oral contraceptive methods and kits that use an estrogenic component defined by a specific chemical class/formula and its precursors paired with a progestogenic component dosed in levonorgestrel-equivalent units, with an express carve-out: the method does not employ co-administration of an LHRH composition. The independent claim 1 is broad in administration route (oral), delivery schedule (further constrained in dependent claims), and estrogen selection (formula-based estrogen class plus “precursors” that can liberate the estrogen structure in vivo). The kit claims in claims 3 to 10 expand commercial coverage to multi-unit oral dosing packs with specified unit counts and dose-range architectures, again with no LHRH content in the oral dosage units.
Bottom line for freedom-to-operate (FTO): If a generic or branded entrant attempts to reproduce the same contraception regimen using an orally administered estrogenic component that falls within the claimed formula/derivative/precursor scope and pairs it with a progestin within the claimed levonorgestrel-equivalent dosing framework, the core infringement risk centers on (i) whether the estrogen “precursor” chemistry liberates the same estrogen at the intended site/time and (ii) whether the progestin amount and regimen structure match dependent claims. The LHRH exclusion provides a clean design path only if competitors truly avoid any LHRH co-administration (a low-probability concern for routine combined oral contraceptives).
What patents protect US 7,732,430 contraceptive method claims (oral estrogen-progestin) and related derivative estrogen scopes?
Claim 1 scope in plain claim-logic
Independent claim 1 covers a contraceptive method comprising:
- Oral administration to a mammalian female of childbearing capability.
- An estrogenic component selected from substances represented by a formula (substituent pattern constraints on R1-R4 and hydroxyl groups R5-R7).
- Or precursors capable of liberating a substance according to that formula when used in the method.
- Precursors are derivatives where at least one hydroxyl hydrogen is substituted by an acyl radical (carboxylic, sulfonic, or sulfamic acid, C1-25), tetrahydrofuranyl, tetrahydropyranyl, or a glycosidic residue containing 1–20 glycosidic units per residue.
- A progestogenic component administered in an effective amount to inhibit ovulation.
- A key limitation: no co-administration of an LHRH composition.
This is a combined method-of-use claim with a chemical-genus estrogen definition and a prodrug/precursor system that can still infringe even if the administered molecule is not the parent estrogen, so long as it liberates the claimed estrogen in the body.
What the “precursors” do to infringement analysis
The precursor language expands scope beyond a single API. It captures prodrug-style ester ethers or glycosides so long as:
- the precursor is a derivative of an estrogen fitting the claimed formula, and
- at least one hydroxyl is substituted in one of the listed ways, and
- the precursor is capable of liberating the claimed estrogen “when used in the present method.”
For design-around strategies, this is a major barrier: changing to a different prodrug format may or may not fall outside the enumerated chemical substitution families.
Dependent claim progestin dosage and dosing schedule
The estate includes several layers of method specificity:
- Claim 2 (progestin dose range): progestogenic component amount equivalent to 0.3 to 20 µg levonorgestrel per kg bodyweight per day.
- Claim 11 (duration for ovulation inhibition): effective to inhibit ovulation for at least 20 days.
- Claims 14–20 (regimen duration and interruption structure):
- “uninterrupted” estrogen and/or combination dosing for at least 10 days (claims 14–16),
- extended interruption-free combinations up to at least 28 days (claim 17),
- “menses induction” interruption structure (claim 18: interval ≥2 days without either hormone),
- alternating estrogen-only after combined dosing (claim 19: estrogen-only for 3–18 consecutive days after combined administration),
- at least once-daily dosing during ≥10 days (claim 20).
These dependent claims are where generic entrants face the highest regimen-specific infringement risk: many generic labels map to 21/7, 24/4, extended-cycle, or other schedules that could land inside these ranges.
How many patents cover US 7,732,430’s estrogen-prodrug/precursor genus and kit packaging, and what claim positions dominate?
A complete “how many patents cover” analysis requires the full patent family set (continuations, divisionals, foreign equivalents, and citing/related continuations). The prompt provides only the claim text of US 7,732,430, not the rest of the family. Under the constraints, a complete count cannot be produced.
What can be concluded from the claim architecture itself:
Dominant positions inside US 7,732,430
- Estrogen genus and precursor mechanism (core chemistry scope).
- No-LHRH limitation (tactical carve-out).
- Progestin dose converted to levonorgestrel-equivalent (broad progestin coverage via dosing equivalence).
- Regimen duration and interval structure (extended-use contraception; menses induction design).
- Kit configuration and unit counts (commercialization coverage even if method is performed with a packaged regime).
Kit claims: claim-by-claim expansion
Claim 3: pharmaceutical kit with ≥20 oral dosage units, where:
- at least 10 units contain 0.01 to 20 mg estrogenic component, and
- at least 10 units contain progestogenic component amount equivalent to 30–750 µg levonorgestrel,
- estrogen is still limited to the genus formula/precursors,
- oral dosage units do not contain an LHRH composition.
Claims 4–10 further constrain kit unit count mixes and combinatorial presence/absence across units:
- Claim 4: at least 10 units contain estrogen (0.01–20 mg) and contain progestin at 30–750 µg levonorgestrel equivalent.
- Claim 5: at least 20 units contain both estrogen and progestin in the combination.
- Claim 6: 20–35 units total, with specified partitioning:
- 10–35 units with combination in indicated amounts,
- 0–25 units with estrogen-only,
- 0–8 units with hormone-free units.
- Claim 7: ≥28 units total, all units contain the combination.
- Claim 8: at least 3 units hormone-free (no estrogen, no progestin).
- Claims 9–10: additional partitioning ranges by unit count, including “at most 1” hormone-free unit in claim 10.
Kit scope matters for generic and label-copy risk
Kit claims can be easier to trigger than method claims when a competitor sources to match packaging configurations. If the competitor sells the same hormone schedule as a set of oral tablets in a pack meeting unit-count partitions and dose ranges, kit infringement may occur even when the method is argued as “label differences,” depending on how infringement is assessed in the jurisdiction and how the kit is marketed/used.
When does US 7,732,430 lose exclusivity (expiration mechanics, term), and what launch windows should generics test?
The prompt does not provide the patent filing date, grant date, or any PTA/adjustments. A precise exclusivity timeline cannot be computed from the provided information.
What can be inferred from claim type:
- US patents like this typically run on fixed term from earliest non-provisional filing date, less any adjustments, and are independent of FDA exclusivity (which applies to new drug approvals rather than device-type “kit” claims).
- For contraceptives, generics often rely on ANDA pathways only if the product is an NDA-listed small molecule. If the listed product is already generic, the remaining patent barriers often shift to Paragraph IV or design-around rather than market exclusivity.
A launch-window analysis that produces exact dates requires the underlying patent metadata.
What Orange Book status affects US 7,732,430 and what generic entry risks exist for oral contraceptives within this claim scope?
No Orange Book listings, referenced NDA numbers, or associated marketed products are provided in the prompt. A claim-anchored Orange Book status mapping cannot be created.
From the claim’s content, the regulatory risk contours are still clear:
- If a marketed contraceptive uses an estrogen that matches the claimed formula genus (or a specified precursor that liberates that estrogen), and pairs it with progestin dosed within the claimed levonorgestrel-equivalent range, the Orange Book patent listing likely drives ANDA Paragraph IV strategy.
- If the marketed product uses a different estrogen (non-matching formula genus) or uses a precursor chemistry outside the enumerated categories, the primary infringement theory weakens at the chemistry-selection element.
How strong is the patent estate for US 7,732,430: novelty levers, claim breadth, and likely invalidity pressure points?
Strength levers built into claim language
- Chemical-genus estrogen selection: The claim does not name a single estrogen; it defines a formula class (R1-R4 and R5-R7 constraints).
- Prodrug precursor enumeration: The precursor substitutions are listed in categories that can be relatively hard to “escape” if competitors use typical prodrug approaches involving esters, sulfonates, or glycosides that meet the enumerated families.
- Functional liberation requirement: “precursors capable of liberating” ties infringement to performance (in vivo liberation), not just structure of the administered molecule.
- Dose equivalence to levonorgestrel: This broadens progestin matching because competitors can choose different progestins if they are administered to be equivalent in levonorgestrel microgram terms (depending on how equivalence is established and proven).
- Regimen structure: Dependent claims capture extended and interrupted regimens, which are common in contraceptive product differentiation.
Likely pressure points (without using unsupported art citations)
While prior art specifics are not provided, the strongest attack angles for a claim like this typically align with:
- Scope overlap between the estrogen genus and prior art estrogens or estrogen prodrugs used in contraception.
- “Capable of liberating” breadth that may be challenged for enablement or definiteness arguments if the genus is wide.
- Equivalence-based progestin dosing: courts frequently scrutinize how equivalence is defined and whether it introduces indefiniteness or requires a clear conversion metric.
Because the prompt includes no prosecution history, prior art list, or litigation record, invalidity strength cannot be rated with evidence-based citations.
Which design-arounds are most likely to avoid US 7,732,430 infringement (chemistry, precursor families, and regimen changes)?
Chemistry-based design-out
To avoid the independent claim, a competitor must defeat at least one of:
- the estrogen structure class defined by the formula constraints, or
- the precursor category and liberation requirement.
Practical design direction implied by the claim:
- use an estrogen not falling inside the specified R-group constraints, and/or
- use a precursor not based on the enumerated acyl radical families (hydrocarbon carboxylic/sulfonic/sulfamic C1-25), and/or tetrahydrofuranyl/tetrahydropyranyl, and/or glycosidic residues with 1–20 glycosidic units, and/or
- ensure the administered precursor does not “liberate” the claimed estrogen under the method conditions.
Regimen-based design-out
Even if the estrogen/progestin chemistry falls into scope, dependent claims add regimen specificity:
- avoid the claimed uninterrupted windows (≥10 days, ≥20 days, ≥28 days) and
- avoid the particular interruption interval (claim 18) and estrogen-only after combination windows (claim 19).
A competitor could attempt to design a schedule outside these bounds. Whether that prevents infringement depends on claim construction for “at least” limitations and whether method claim 1 is infringed regardless of dependent claim timing (independent claim 1 is not limited to 10/20/28-day minima; dependent claims are).
LHRH co-administration avoidance
Because claim 1 explicitly states the method does not employ co-administration of an LHRH composition, competitors are generally already outside that limitation for typical contraceptive regimens. This is not a high-leverage design-around.
What patent litigation or settlements involve US 7,732,430 and how do they affect generic launch scenarios?
No litigation docket entries, case captions, settlement dates, or Paragraph IV filings are provided. A litigation impact analysis cannot be produced under the constraints.
How do method-of-use claims compare with kit claims in US 7,732,430 for enforcement and licensing leverage?
Method claims (claims 1–22)
- Infringement analysis is anchored in what is administered, the route (oral), and the functional pharmacologic outcome (inhibit ovulation), plus timing/dosing limitations in dependent claims.
- Enforcement typically targets the end-to-end method steps: prescribing, dispensing, and patient use, depending on jurisdictional rules for method claim enforcement.
Kit claims (claims 3–10)
- Infringement analysis can be anchored in product composition and packaging at point of sale.
- Kit claims can strengthen licensing leverage because a product launch is tied to a physical pack meeting unit-count and hormone content ranges.
Commercial implication: If a competitor launches a kit that meets the unit architecture and dose ranges, kit claims can block commercialization even if the method-of-use argument is contested on how patients follow schedules or on how “effective amount” is proven in the label context.
Key Takeaways
- US 7,732,430 claims oral contraceptive methods and pharmaceutical kits built around a formula-defined estrogen genus plus enumerated ester/ether/glycoside-style precursors that can liberate that estrogen, paired with progestin dosed by levonorgestrel-equivalent amounts.
- The patent’s risk core is estrogen selection plus precursor liberation and progestin dose equivalence, with additional infringement layers from extended/interrupted regimen timing and kit unit-count configurations.
- The independent claim includes a clear limitation: no co-administration of an LHRH composition, which is typically not implicated in standard contraceptive products.
- A credible exclusivity/launch-window analysis, Orange Book mapping, and litigation/settlement impact require patent metadata and prosecution/portfolio associations not present in the prompt.
FAQs
-
Does US 7,732,430 cover prodrugs if the administered estrogen is not the parent molecule?
Yes. Claim 1 covers precursors capable of liberating the claimed estrogen when used in the method.
-
What progestin dose is specified in US 7,732,430?
Claim 2 limits the progestogenic component to an amount equivalent to 0.3 to 20 µg levonorgestrel per kg per day.
-
Do the kit claims require a minimum number of units?
Yes. Claim 3 requires at least 20 oral dosage units, with minimum counts containing estrogen and progestin content in specified ranges.
-
Can a competitor avoid the patent by changing the dosing schedule?
Dependent claims include specific uninterrupted and interruption windows (≥10, ≥20, ≥28 days; ≥2-day hormone-free interval; estrogen-only after combination), but independent claim 1 still covers the broader method elements.
-
Is LHRH co-administration part of the claimed regimen?
No. The claims expressly state the method does not employ co-administration of an LHRH composition.
References
- United States Patent 7,732,430 (claims provided in prompt).
